The nation of Zimbabwe has rejected a major American health deal worth 367 million US dollars (272 million pounds) spanning five years due to the United States' demand for sensitive data.
The decision became public following a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the deal was "skewed".
A government spokesperson has since clarified that the United States was requesting genetic material for scientific study and commercial purposes while refused to share the resulting advantages from future treatments.
"We will now turn to the difficult and regrettable task of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had furnished over $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more talks to reach a agreement agreeable to both sides so the nation's critical HIV treatment initiative can continue.
Wider Implications
This rejection comes after a comparable case in neighbouring Kenya, where a high court blocked a similar health funding agreement after legal challenges were filed about the security of Kenyans' medical information.
After resuming office last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump claimed its spending was "inefficient" and his administration was seeking direct bilateral agreements to boost openness and responsibility.
According to reports, 16 African countries have to date agreed to these new agreements, representing over $18.3bn in committed funds.
Details of the Rejected Agreement
The money for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership could have provided immense benefits for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy through US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to surrender its genetic material and health information over an extended period, with no equivalent promise of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"Put simply, our nation would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be available to our citizens should a new disease outbreak arise."
National Interest and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending structures previously established via the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with potential global health emergencies.
"This framework is intended to ensure that when a nation contributes its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to create them."
These objections regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome further dialogue with our US partners on how future co-operation could be arranged in a way that respects the independence and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but urged that negotiations must proceed considering much of the nation's HIV programmes depended on external financing.
"If specific concerns arise, such as those involving data governance or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," the group added.
The situation underscores the continuing tensions between accepting crucial international aid and protecting national sovereignty in an increasingly data-driven world.